Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia

被引:28
|
作者
Achtyes, Eric [1 ,2 ]
Simmons, Adam [3 ]
Skabeev, Anna [3 ]
Levy, Nikki [3 ]
Jiang, Ying [3 ]
Marcy, Patricia [4 ]
Weiden, Peter J. [3 ]
机构
[1] Cherry Hlth, Grand Rapids, MI USA
[2] Michigan State Univ, Coll Human Med, Grand Rapids, MI 49503 USA
[3] Alkermes Inc, Waltham, MA USA
[4] Northwell Hlth Syst, Vanguard Res Grp, Manhasset, NY USA
来源
BMC PSYCHIATRY | 2018年 / 18卷
关键词
Adherence; Antipsychotics; Weight; Side effects; PSYCHIATRY WFSBP GUIDELINES; BIOLOGICAL TREATMENT; ANTIPSYCHOTIC-DRUGS; REPORTED OUTCOMES; WORLD FEDERATION; UPDATE; 2012; MANAGEMENT; SOCIETIES;
D O I
10.1186/s12888-018-1856-y
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Despite the availability of numerous antipsychotic medications, many patients with schizophrenia continue to experience side effects that contribute to the overall burden of the illness. The present survey of patients with schizophrenia and schizoaffective disorder aimed to assess patient attitudes toward antipsychotic treatment, and understand key factors about willingness to try a new medication. Methods: A cross-sectional survey was administered to 250 patients with a primary clinical diagnosis of a schizophrenia spectrum disorder across five outpatient clinics in the United States. The survey included self-reported gender, age, weight, and height, and questions about the importance of efficacy and side effects on the decision to take a prescribed antipsychotic medication. Results: Patients rated efficacy and side effects as important attributes of antipsychotic treatment, with 93.6% and 83.6% of patients listing these as "very" or the "most" important factors in taking prescribed medication. A total of 87.6% of respondents identified the ability to think more clearly as an important property of their medication. Patients identified weight gain, physical restlessness, and somnolence as important side effects of current treatments ("very" or "most" important by 61.6%, 60.8%, and 58.8%, respectively). When asked about willingness to change antipsychotic medication, anticipated weight gain had a negative influence on willingness to try the new treatment, with 22.0% declining to try a medication that would lead to weight gain of 2.7-4.5 kg (6-10 lb), 34.0% declining for anticipated weight gain of 5.0-9.1 kg (11-20 lb), and 52.4% declining for anticipated weight gain greater than 9 kg (20 lbs). Conclusion: Patients living with schizophrenia spectrum disorders are influenced by many factors when considering whether to take their medication, including efficacy and side effects. It is important for clinicians to assess specific patient concerns to develop a comprehensive treatment plan that maximizes adherence to the prescribed therapy.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia
    Eric Achtyes
    Adam Simmons
    Anna Skabeev
    Nikki Levy
    Ying Jiang
    Patricia Marcy
    Peter J. Weiden
    BMC Psychiatry, 18
  • [2] Idiopathic Thrombocytopenia Side-Effect of Lithium in a Patient with Schizophrenia
    Sakic, Branislav O.
    Dadasovic, Josip Dj
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 23 (02): : 180 - 182
  • [3] SCHIZOPHRENIA-MELANOSIS - CAUSE OR SIDE-EFFECT
    GREINER, AC
    NICOLSON, GA
    LANCET, 1965, 2 (7423): : 1165 - &
  • [4] Weight gain as side-effect of olanzapine and risperidone in adolescent patients with schizophrenia
    van Bruggen, JM
    Linszen, DH
    Dingemans, PMAJ
    SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 196 - 196
  • [5] BENOXAPROFEN - SIDE-EFFECT PROFILE IN 300 PATIENTS
    HALSEY, JP
    CARDOE, N
    BMJ-BRITISH MEDICAL JOURNAL, 1982, 284 (6326): : 1365 - 1368
  • [6] Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia
    Sevy, S
    Nathanson, K
    Schechter, C
    Fulop, G
    SCHIZOPHRENIA BULLETIN, 2001, 27 (04) : 643 - 651
  • [7] Efficacy and metabolic profile of bifeprunox in patients with schizophrenia
    Barbato, L. M.
    Newcomer, J. W.
    Heisterberg, J.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 419 - 419
  • [8] SIDE-EFFECT PROFILE OF CYCLOSPORINE-A IN PATIENTS TREATED FOR PSORIASIS
    KRUPP, P
    MONKA, C
    BRITISH JOURNAL OF DERMATOLOGY, 1990, 122 : 47 - 56
  • [9] PREFERENCES FOR ATTRIBUTES OF ORAL ANTIPSYCHOTIC TREATMENTS: SURVEY RESULTS OF PATIENTS LIVING WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER
    Doane, M.
    Boeri, M.
    Panchmatia, H.
    Citrome, L.
    Sajatovic, M.
    VALUE IN HEALTH, 2023, 26 (06) : S320 - S320
  • [10] Modeling Effects of Side-Effect Probability, Side-Effect Severity, and Medication Efficacy on Patients With Multiple Sclerosis Medication Choice
    Jarmolowicz, David P.
    Reed, Derek D.
    Bruce, Amanda S.
    Lynch, Sharon
    Smith, Julia
    Bruce, Jared M.
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2018, 26 (06) : 599 - 607